Navigation Links
ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO

are presented or published. Following is a list of the abstracts related to ARQ 197 and ARQ 501 that have been accepted at the ASCO and AACR meetings.

ASCO Abstracts

For oral presentation

-- A Phase 1 dose escalation study of ARQ 197, a selective inhibitor of the c-Met receptor in patients with metastatic solid tumors

For publication in ASCO proceedings

-- A Phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma

-- A Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS)

AACR Abstracts

-- Pharmacokinetics of a novel PGA-ARQ 501 conjugate in mouse xenografts

-- Mass balance and characterization of the Metabolites of ARQ 501 ((beta)-lapachone), a checkpoint pathway activator in clinical development

-- Pharmacodynamic biomarkers for checkpoint pathway activator ARQ501 in a human colon xenograft model

-- Selective induction of necrotic cell death in cancer cells by (beta)-lapachone through activation of DNA damage response pathway

-- Evaluation of biomarkers for HGFR/c-Met inhibitor ARQ 197 in a human xenograft model

-- Functional chemogenomics approach to identify checkpoint pathway activators against cancer

-- Selective killing of cancer cells by activation of human checkpoint kinase 2

-- ARQ 197, a highly selective small molecule inhibitor of c-Met, inhibits invasive and metastatic growth of cancer cells

-- ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells

-- Broad spectrum anti-cancer activity of ARQ 197, a highly selective oral c-Met Inhibitor, in multiple xenograft models

-- Anti-metastatic activity of ARQ 197, a highly selective oral small molecule inhibitor of c-Met,
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/22/2013)... WORCESTER, Mass. and TORONTO ... www.generex.com ) (OTCBB: GNBT) today announced three presentations demonstrating ... developed by its wholly-owned subsidiary, Antigen Express, Inc. ( ... annual meeting of the American Society of Clinical Oncology ... from May 31 through June 4, 2013. ...
(Date:5/22/2013)... 2013  Grifols, a global healthcare company based in ... a study demonstrating that a higher dose of PROLASTIN ... of the alpha 1 protein in patients with ... considered within the normal range for healthy individuals. AAT ... levels of the alpha 1 proteinase inhibitor (A1PI) ...
(Date:5/22/2013)... LAKES, N.J. , May 22, 2013  BD ... a leading global medical technology company, announced today the ... is BD,s fifth Sustainability Report and it continues to ... "We believe the principles of shared ... and addressing healthcare challenges of societies — are fundamental ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3
... Accuray Incorporated (Nasdaq: ARAY ) ... announced acquisition of TomoTherapy Incorporated (Nasdaq: TOMO). The ... best-in-class technologies to fight cancer.  The combined company ... leading-edge treatment solutions that revolve around the patient. ...
... 13, 2011 Guidelines that reduce the use of mechanical ... of respiratory support can profoundly affect those children,s outcomes while ... researchers at Children,s Hospital Boston. The team, ... Medicine at Children,s Hospital Boston and the Neonatal Intensive Care ...
Cached Medicine Technology:Accuray Successfully Completes Acquisition of TomoTherapy 2Accuray Successfully Completes Acquisition of TomoTherapy 3Accuray Successfully Completes Acquisition of TomoTherapy 4Guidelines for Ventilator Use Help Premature Infants Breathe Easier 2Guidelines for Ventilator Use Help Premature Infants Breathe Easier 3
(Date:5/22/2013)... May 22, 2013 Nearly 50,000 veterans ... (BVA) in fiscal year 2012, with even more—54,033—expected by ... longer for a decision as the agency reports reduced ... provides veterans disability appeal services. The BVA ... Affairs. , Although the BVA received 49,611 cases in ...
(Date:5/22/2013)... A new study shows there is a gender ... American young children one that does not appear ... United States, girls had higher levels of self-regulation than ... their behavior and impulses, follow directions, and persist on ... and college completion, in past studies by Oregon State ...
(Date:5/22/2013)... 22, 2013 Successful Therapy for ... O’Laughlin Psychotherapy in the Silver Lake community of ... ages as progression to existing Parents and Couples ... into parenting therapy has always been suggested, but ... Psychotherapy now specializes in all aspects of ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Diversity Focus ... Handicap This! The performance promotes awareness that physical ... The Handicap This! performance will be held Friday, June ... School auditorium. Tickets for Handicap This! can be ... helps audiences measure the level to which their mind ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Today, Zane ... Alabama Health Insurance Exchange . Zane Benefits, which provides ... benefits, is the leader in defined contribution plans ... to Zane Benefits’ website, beginning in 2014 as part ... for individuals and small businesses will become available through ...
Breaking Medicine News(10 mins):Health News:Veterans Disability Appeals See Fewer Decisions in FY2012, Reports Allsup 2Health News:'Boys will be boys' in US, but not in Asia 2Health News:'Boys will be boys' in US, but not in Asia 3Health News:Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children 2Health News:Handicap This! Comes to Marion, Iowa 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3
... with $150K Donation to the University of Pittsburgh ... After losing a battle to Merkel Cell Carcinoma, an aggressive and deadly ... through a donation by the Al Copeland Foundation to the University ... Copeland Day on June 28, 2009. , , Al Copeland ...
... June 30 Biopure Corporation (Nasdaq: BPUR ) ... by letter dated June 24, 2009, that it is out of ... be delisted. The notice stated that the company no longer ... on the Nasdaq Capital Market. , , Nasdaq advised that ...
... reduced pain and restored mobility in tendinitis patients, study ... of people suffer from tendinitis of the rotator cuff, ... pain and restore mobility of the shoulder, Italian researchers ... tendinitis, which involves small calcium deposits within the tendons ...
... high percentage of women responded favorably to a bioidentical ... , MAPLE GROVE, Minn., June 30 Upsher-Smith ... to determine the response rates to three doses of ... 57th Annual Clinical Meeting of the American College of ...
... SOUTH SAN FRANCISCO, Calif., June 30 Hyperion Therapeutics, ... development of therapies that address critical unmet needs in ... has closed a $60 million Series C financing. New ... financing. Series A and B investors Highland Capital Partners, ...
... the most out of treatment during the summer months and beyond ... the arrival of summer means more time outdoors, with trips to ... more enjoyable than soaking up the sun and having fun with ... actually mean a worsening of symptoms and the need for extra ...
Cached Medicine News:Health News:Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 2Health News:Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 3Health News:Nonsurgical Treatment May Ease Rotator Cuff Injury 2Health News:New Data: Efficacy and Responder Analyses of Divigel(R) (estradiol gel) 0.1 percent for the Treatment of Menopause 2Health News:New Data: Efficacy and Responder Analyses of Divigel(R) (estradiol gel) 0.1 percent for the Treatment of Menopause 3Health News:New Data: Efficacy and Responder Analyses of Divigel(R) (estradiol gel) 0.1 percent for the Treatment of Menopause 4Health News:New Data: Efficacy and Responder Analyses of Divigel(R) (estradiol gel) 0.1 percent for the Treatment of Menopause 5Health News:Hyperion Therapeutics Raises $60 Million Series C 2Health News:Hyperion Therapeutics Raises $60 Million Series C 3Health News:Summertime Sun Exposure Can 'Burn' Acne Sufferers in More Ways than One 2Health News:Summertime Sun Exposure Can 'Burn' Acne Sufferers in More Ways than One 3
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
The Sonic WAVE™is the first market-ready Alternative to Ultrasound...
... The Stat Profile pHOx series consists of six ... and critical care profiles. Measured tests include pH, ... %, hematocrit, hemoglobin, sodium, potassium, ionized calcium, chloride, ... less than one minute. Its space saving design ...
... compact Sleepscan Traveler provides the ultimate flexibility ... PSG data in the home, a patient ... sleep studies utilize the same powerful Sleepscan ... Sleepscan Traveler studies take full advantage of ...
Medicine Products: